financetom
Business
financetom
/
Business
/
Anthropic bolsters AI model Claude's coding, agentic abilities with Opus 4.5
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anthropic bolsters AI model Claude's coding, agentic abilities with Opus 4.5
Nov 24, 2025 11:39 AM

(Reuters) -Artificial intelligence startup Anthropic unveiled an upgraded Opus model on Monday, boosting Claude's ability to write detailed code, create sophisticated agents and streamline enterprise workflows through spreadsheet and financial analysis.

The new model comes as Amazon ( AMZN ) and Alphabet-backed Anthropic races against OpenAI and other rivals to develop cutting-edge large language models aimed at achieving capabilities that could surpass human intelligence.

Opus 4.5 ranks among the most powerful models in the Claude family, offering deep reasoning and memory, coding and a versatile performance across a range of computer applications, including financial tasks such as modeling and forecasting.

Its agents autonomously refine their own capabilities and store insights from past work to apply at a later date, Anthropic said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
Jul 8, 2024
Monday, IDEAYA Biosciences Inc ( IDYA ) released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients (NSCLC). “IDE397 is a potential first-in-class MAT2A inhibitor, that is being advanced as a monotherapy agent in priority MTAP-deletion solid tumor types and in high conviction rational combinations, including with Amgen’s investigational...
SolarEdge Technologies Inventory, Demand Headwinds to Taper Off in 2025, BofA Says
SolarEdge Technologies Inventory, Demand Headwinds to Taper Off in 2025, BofA Says
Jul 8, 2024
12:24 PM EDT, 07/08/2024 (MT Newswires) -- SolarEdge Technologies' ( SEDG ) current share price slump is factoring in an unlikely worst-case scenario of inventory writedowns and liquidity challenges, BofA Securities said in a note Monday. Residential demand is softening and the European market is still facing substantial inventory headwinds. There is a concern that inventory congestion and reduced sales...
TD's chief compliance officer departs amid US anti-money laundering probe
TD's chief compliance officer departs amid US anti-money laundering probe
Jul 8, 2024
TORONTO (Reuters) - TD Bank's chief compliance officer has left the bank, according to a memo sent internally, at a time the Canadian lender faces U.S. regulators and the Justice Department in a probe related to its anti-money laundering program. Monica Kowal, who joined the bank in 2017, left the company this week, and will be replaced by Deputy Chief...
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Jul 8, 2024
Tonix Pharmaceuticals Holding Corp ( TNXP ) shares are trading lower by 11.3% to $0.71 during Monday’s session after the company announced receipt of the formal minutes from a recent pre-New Drug Application meeting with the FDA for Tonmya for the management of fibromyalgia. What Happened? Tonix Pharmaceuticals ( TNXP ) earlier Monday announced that it received formal minutes from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved